TNF PHARMACEUTICALS INC (TNFA) Stock Price & Overview
NASDAQ:TNFA • US62856X2018
Current stock price
The current stock price of TNFA is 5.2 USD. Today TNFA is up by 48.15%. In the past month the price decreased by -33.25%. In the past year, price decreased by -96.6%.
TNFA Key Statistics
- Market Cap
- 244.4M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- N/A
- Dividend Yield
- N/A
TNFA Stock Performance
TNFA Stock Chart
TNFA Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to TNFA. When comparing the yearly performance of all stocks, TNFA is a bad performer in the overall market: 99.5% of all stocks are doing better.
TNFA Earnings
TNFA Forecast & Estimates
TNFA Groups
Sector & Classification
TNFA Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
TNFA Ownership
TNFA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 25.7 | 871.596B | ||
| JNJ | JOHNSON & JOHNSON | 18.73 | 578.307B | ||
| MRK | MERCK & CO. INC. | 23.01 | 296.588B | ||
| PFE | PFIZER INC | 9.05 | 154.211B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.06 | 118.584B | ||
| ZTS | ZOETIS INC | 17.03 | 51.124B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.35 | 28.162B | ||
| VTRS | VIATRIS INC | 5.59 | 16.197B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.32 | 11.987B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.421B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.45B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.08B | ||
| CORT | CORCEPT THERAPEUTICS INC | 80.69 | 4.646B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About TNFA
Company Profile
TNF Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of drug products to extend healthy lifespan. The company is headquartered in New York City, New York and currently employs 2 full-time employees. The company went IPO on 2008-07-24. The firm is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. Isomyosamine is a drug platform based on a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. Isomyosamine is being developed to treat diseases and disorders marked by acute or chronic inflammation. Isomyosamine works by regulating the release of numerous pro-inflammatory cytokines. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the CBD market, which includes both Food and Drug Administration (FDA) approved drugs and CBD products not regulated as drugs.
Company Info
IPO: 2008-07-24
TNF PHARMACEUTICALS INC
1185 Avenue Of The Americas, Suite 249
New York City NEW YORK US
Employees: 2
Phone: 18568488698
TNF PHARMACEUTICALS INC / TNFA FAQ
Can you describe the business of TNF PHARMACEUTICALS INC?
TNF Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of drug products to extend healthy lifespan. The company is headquartered in New York City, New York and currently employs 2 full-time employees. The company went IPO on 2008-07-24. The firm is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. Isomyosamine is a drug platform based on a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. Isomyosamine is being developed to treat diseases and disorders marked by acute or chronic inflammation. Isomyosamine works by regulating the release of numerous pro-inflammatory cytokines. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the CBD market, which includes both Food and Drug Administration (FDA) approved drugs and CBD products not regulated as drugs.
What is the stock price of TNF PHARMACEUTICALS INC today?
The current stock price of TNFA is 5.2 USD. The price increased by 48.15% in the last trading session.
Does TNFA stock pay dividends?
TNFA does not pay a dividend.
How is the ChartMill rating for TNF PHARMACEUTICALS INC?
TNFA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is the GICS sector and industry of TNFA stock?
TNF PHARMACEUTICALS INC (TNFA) operates in the Health Care sector and the Pharmaceuticals industry.
Can you provide the market cap for TNF PHARMACEUTICALS INC?
TNF PHARMACEUTICALS INC (TNFA) has a market capitalization of 244.40M USD. This makes TNFA a Micro Cap stock.
What is the ownership structure of TNF PHARMACEUTICALS INC (TNFA)?
You can find the ownership structure of TNF PHARMACEUTICALS INC (TNFA) on the Ownership tab.